Transformational Deal to Create a Global CDMO Powerhouse in Pharma Innovation
Hyderabad, March 28, 2025 – In a major development for the pharmaceutical industry, Suven Pharmaceuticals Ltd. (BSE: 530239, NSE: SUVENPHARM) has received approval from the National Company Law Tribunal (NCLT) for the merger of Cohance Lifesciences Limited into and with Suven Pharmaceuticals. The order was officially pronounced on March 27, 2025, and published on the NCLT website the same day (https://nclt.gov.in/).
The merger is expected to strengthen Suven Pharmaceuticals’ position as a leading Contract Development and Manufacturing Organization (CDMO), creating a diversified and future-ready pharma powerhouse.
Key Details of the Merger
📌 When Will the Merger Take Effect?
- The amalgamation will be effective from the first business day of the month immediately following the fulfillment of all conditions outlined in the scheme.
- This includes obtaining regulatory approvals, such as clearance from the Department of Pharmaceuticals.
- Suven Pharmaceuticals anticipates completing the merger process by Q1 FY26.
📌 Strategic Impact of the Merger
- The merged entity will focus on three high-growth verticals: 1️⃣ Antibody Drug Conjugates (ADCs)
2️⃣ Oligonucleotides
3️⃣ Small Molecules - The combined company will operate as a fully integrated CDMO, offering end-to-end solutions to global pharmaceutical innovators.
- Strengthened Specialty CDMO and API+ business segments, unlocking operational synergies and scaling up manufacturing capabilities.
Link of the intimation to the exchange on the merger approval from NCLT: https://www.bseindia.com/xml-
Leadership Perspectives: A Vision for Growth
Vivek Sharma, Executive Chairman, Suven Pharmaceuticals:
“The NCLT approval marks a milestone moment for both companies, as we embark on a transformative phase. This merger enhances our global capabilities, particularly in the growing and highly specialized areas of ADCs. With Cohance’s unique technological platform in ADCs, we are well-positioned to become a $1 billion revenue company in the next five years with higher CDMO contribution.”
Dr. V. Prasada Raju, Managing Director, Suven Pharmaceuticals:
“The approval of the merger is a significant step in our journey to build an innovation-led CDMO platform from India. The combined expertise of Suven and Cohance positions us strongly in high-growth areas such as Antibody Drug Conjugates, Oligonucleotides, and complex Small Molecules. These segments represent the future of pharmaceutical innovation, and our integrated approach—from development to commercial manufacturing—aims to deliver high-impact solutions to global clients.”
Why This Merger Matters for the Pharma Industry
🔹 Expanding Global Reach: The combined entity will enhance Suven’s presence in key international markets, catering to pharmaceutical giants seeking advanced CDMO solutions.
🔹 Boosting Innovation: With Cohance’s expertise in ADC technology, the company will now be able to accelerate drug development and commercialization for cutting-edge therapies.
🔹 Driving Long-Term Value: The integration of API+ and Specialty CDMO business segments will create new revenue streams and efficiency-driven cost savings.
🔹 Future-Proofing India’s CDMO Leadership: The merger strengthens India’s standing in global pharmaceutical manufacturing, reinforcing the country’s role as a hub for complex drug development.
What’s Next? Timeline & Industry Expectations
📅 Expected Completion: Q1 FY26
📊 Projected Growth: Aim to achieve $1 billion in revenue within the next five years
🌍 Target Market: Global pharmaceutical innovators in the oncology, neurology, and rare disease segments
With the approval now in place, Suven Pharmaceuticals is set to redefine India’s presence in the global CDMO industry. Investors, industry experts, and pharmaceutical innovators will be watching closely as this merger unfolds, shaping the future of pharmaceutical manufacturing and drug development.
🔎 Will this merger position Suven Pharmaceuticals as a global CDMO leader? Stay tuned for more updates!
